ImmunoCellular Therapeutics (IMUC) Misses Q4 EPS by 16c

ImmunoCellular Therapeutics (NYSE: IMUC) reported Q4 EPS of ($1.36), $0.16 worse than the analyst estimate of ($1.20).

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.

You May Also Be Interested In

• Carnival Corp. (CCL) Tops Q3 EPS by 8c
• SU Group reports narrowed loss as revenue falls 20% in first half
• Perimeter Solutions SA (PRM) PT Lowered to $38 at UBS, Buy Rating Maintained Into Q3 Print